Literature DB >> 24838690

Outcome and toxicity profile after brachytherapy for squamous cell carcinoma of the nasal vestibule.

Djoeri Lipman1, Lia C Verhoef1, Robert P Takes2, Johannes H Kaanders1, Geert O Janssens1.   

Abstract

BACKGROUND: The purpose of this study was to evaluate outcome and toxicity profile after primary brachytherapy for squamous cell carcinoma of the nasal vestibule.
METHODS: A retrospective study was conducted for patients with Wang classification T1 to 2 cN0 squamous cell carcinoma of the nasal vestibule who received primary treatment with brachytherapy between 1992 and 2010. Tumor control, acute skin, mucosal, and late cartilage toxicity were scored.
RESULTS: Of 60 patients (T1, 50; T2, 10), 38 were treated with an interstitial implant and 22 by a mold technique. The 3-year local, regional, and locoregional control rates were 91%, 93%, and 84%, respectively. Tumor diameter <1.5 cm resulted in a better local (p = .02) and regional (p = .05) control. The cumulative incidence of moist skin desquamation and confluent mucositis was 64% and 82%, respectively. The actuarial incidence of chondritis and/or chondronecrosis was 19%.
CONCLUSION: Primary brachytherapy for Wang T1 to 2 squamous cell carcinoma of the nasal vestibule offers excellent tumor control rates with acceptable toxicity and preservation of anatomy.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  brachytherapy; nasal vestibule; outcome; squamous cell carcinoma; toxicity

Mesh:

Year:  2014        PMID: 24838690     DOI: 10.1002/hed.23758

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  3 in total

1.  Local control and intermediate-term cosmetic outcome following IMRT for nasal tumors : An update.

Authors:  Yuki Mukai; Stefan Janssen; Christoph Glanzmann; David Holzmann; Gabriela Studer
Journal:  Strahlenther Onkol       Date:  2016-12-05       Impact factor: 3.621

2.  Carbon Ion Beam Boost Irradiation in Malignant Tumors of the Nasal Vestibule and the Anterior Nasal Cavity as an Organ-Preserving Therapy.

Authors:  Fabian Eberle; Rita Engenhart-Cabillic; Markus M Schymalla; Christoph Dumke; Ulrike Schötz; Florentine S B Subtil; Kilian-Simon Baumann; Boris A Stuck; Christine Langer; Alexandra D Jensen; Henrik Hauswald; Stefan Lautenschläger
Journal:  Front Oncol       Date:  2022-02-15       Impact factor: 6.244

3.  Hybrid Intracavitary-Interstitial brachytherapy in a case of nasal vestibule cancer penetrating the hard palate.

Authors:  Naoya Murakami; Go Omura; Wakako Yatsuoka; Hiroyuki Okamoto; Seiichi Yoshimoto; Takao Ueno; Jun Itami
Journal:  BJR Case Rep       Date:  2021-03-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.